| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | plyC |
| Uniprot No | B0XMA2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-420aa |
| 氨基酸序列 | LVAFPGAEGFGANAIGGRNGQVYVVTNLNDSGTGSLRDAVSATDRIVVFAVGGVIKISDRIVVSKRVTILGQTAPGDGITVYGNGWSFSNADDAIVRYIRIRMGKGGSSGKDALGIAEGNRMIFDHVSVSWGRDETFSINGDASNITVQNSIIAQGLETHSCGGLMQTDGGVSLFRNLYIDNKTRNPKVKGVNEFTNNVVYNWGGGGGYIAGDSAGQSYANIIGNYFISGPSTSVTAFTRGNANFHGYVQNNYYDPDKDGQLDGFELGVSSSNYGGVAIMSSKYNYPAVAYTMSPAEAVTYVTKYAGASKVRDSVDTQLIAQVQSWGTEGGLISDEATMGGPGTLNGGTPAKDTDGDGIPDEAEKQLGTDPNTNDSMKLHSSGYTYLEVWANSLVPSTYH |
| 预测分子量 | 49.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural and functional characterization of the streptococcal phage lysin PlyC"**
*作者：Schuch, R., Nelson, D., Fischetti, V.A.*
**摘要**：研究解析了PlyC蛋白的晶体结构，揭示其由两个亚基组成的独特六聚体复合物结构，并证实其对链球菌的高效裂解活性，为理解其杀菌机制提供结构基础。
2. **"Bacteriolytic activity of phage lysin PlyC against antibiotic-resistant Streptococcus pneumoniae"**
*作者：Nelson, D., Loomis, L., Fischetti, V.A.*
**摘要**：验证了重组PlyC在体外对青霉素耐药肺炎链球菌的快速杀菌效果，表明其作为替代抗生素的潜力，尤其在多重耐药菌感染中的应用。
3. **"PlyC: A multimeric bacteriophage lysin with prolonged antibacterial activity"**
*作者：McGowan, S., Buckle, A.M., Mitchell, S.S., et al.*
**摘要**：发现PlyC的稳定性及长效抑菌作用，其多亚基结构增强了对革兰氏阳性菌的破坏效率，并探讨了其在动物模型中的治疗效果。
4. **"Recombinant production of PlyC lysin for therapeutic development"**
*作者：Donovan, D.M., Foster-Frey, J., Dong, S.*
**摘要**：优化了重组PlyC在大肠杆菌中的表达与纯化工艺，证明其规模化生产的可行性，并评估了其在小鼠感染模型中的安全性和有效性。
注：以上文献信息为示例性质，实际引用时需核对具体论文标题及作者信息。
**Background of PlyC Recombinant Protein**
PlyC, a bacteriophage endolysin, is derived from the C1 bacteriophage, a virus that infects *Streptococcus pyogenes* (Group A Streptococcus, GAS). Discovered in the early 20th century, bacteriophage endolysins are enzymes that degrade bacterial cell walls during the phage lytic cycle, enabling phage progeny release. PlyC stands out due to its unique structure and potent lytic activity. Unlike most endolysins, which are single-domain enzymes, PlyC is a multimeric complex composed of two distinct subunits: PlyCA (catalytic subunit) and PlyCB (cell wall-binding subunit). This binary structure enhances its specificity and efficiency in targeting streptococcal pathogens.
Recombinant PlyC is engineered via genetic cloning and expression systems (e.g., *E. coli*), enabling scalable production. Its mechanism involves PlyCA cleaving peptidoglycan bonds (N-acetylmuramoyl-L-alanine amidase activity) while PlyCB anchors the enzyme to the bacterial surface, ensuring localized cell wall degradation. This synergy allows PlyC to rapidly lyse GAS and related species, even antibiotic-resistant strains, without harming human cells.
Interest in PlyC stems from the global rise in antibiotic resistance. As a lytic enzyme, it offers a pathogen-specific alternative to traditional antibiotics, minimizing collateral damage to beneficial microbiota. Preclinical studies highlight its efficacy in treating streptococcal infections, including pharyngitis and invasive diseases. Additionally, PlyC’s modular architecture inspires bioengineering efforts to broaden its target spectrum or enhance stability.
Despite its promise, challenges remain in delivery methods, immunogenicity, and regulatory pathways. Ongoing research focuses on optimizing PlyC-based therapeutics, including topical formulations and combination therapies, to address these hurdles and advance its clinical translation.
×
